Generic Qutenza Availability
Last updated on Nov 6, 2024.
Qutenza is a brand name of capsaicin topical, approved by the FDA in the following formulation(s):
QUTENZA (capsaicin - patch;topical)
-
Manufacturer: AVERITAS
Approval date: November 16, 2009
Strength(s): 8% [RLD]
Has a generic version of Qutenza been approved?
No. There is currently no therapeutically equivalent version of Qutenza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qutenza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
Patent 10,034,841
Issued: July 31, 2018
Inventor(s): Müller Walter & Leonhard Johannes
Assignee(s): LTS Lohmann Therapie-Systeme AGThe invention generally relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer that is anchored to the backing layer by siliconization.
Patent expiration dates:
- September 6, 2025✓
- September 6, 2025
-
Therapeutic patch for transdermal delivery of capsaicin
Patent 8,821,920
Issued: September 2, 2014
Inventor(s): Müller Walter
Assignee(s): LTS Lohmann Therapie Systeme AGThe invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent, in which the therapeutic compound is present in completely dissolved form and the concentration of the therapeutic compound in the microreservoir droplets is below the saturation concentration. The invention furthermore relates to a process for its production and its use in the treatment of neuropathic pain.
Patent expiration dates:
- March 26, 2030✓
- March 26, 2030
-
Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer
Patent 9,226,903
Issued: January 5, 2016
Inventor(s): Mueller Walter & Leonhard Johannes
Assignee(s): LTS Lohmann Therapie-Systeme AGThe invention relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer and is anchored in the backing layer by siliconization.
Patent expiration dates:
- December 15, 2028✓
- December 15, 2028
More about Qutenza (capsaicin topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous topical agents
- Breastfeeding
- En español
Patient resources
Other brands
Zostrix, Icy Hot PM Patch, Capzasin, Salonpas-Hot, ... +16 more
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.